Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMRN NASDAQ:INKT NASDAQ:NMRA NASDAQ:PVLA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$15.50-0.6%$13.88$7.08▼$17.49$322.82M0.8298,955 shs39,244 shsINKTMiNK Therapeutics$19.00-5.3%$11.44$4.56▼$76.00$79.95M0.192.94 million shs138,952 shsNMRANeumora Therapeutics$2.29+23.8%$0.99$0.61▼$17.19$299.23M2.752.27 million shs2.99 million shsPVLAPalvella Therapeutics$38.63+0.5%$25.19$11.17▼$38.74$424.87M-0.11189,879 shs68,685 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin+2.30%-1.64%+23.73%+39.45%-0.74%INKTMiNK Therapeutics-4.70%-13.20%+168.18%+168.54%+121.54%NMRANeumora Therapeutics-2.12%+32.14%+147.99%+146.83%-84.51%PVLAPalvella Therapeutics+6.75%+35.22%+70.50%+50.88%+3,842,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMRNAmarin0.3786 of 5 stars0.53.00.00.02.40.00.6INKTMiNK Therapeutics2.8937 of 5 stars3.43.00.00.03.11.70.6NMRANeumora Therapeutics2.5156 of 5 stars3.13.00.00.01.82.50.6PVLAPalvella Therapeutics1.455 of 5 stars2.60.00.00.01.42.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMRNAmarin 1.00Sell$12.00-22.58% DownsideINKTMiNK Therapeutics 2.75Moderate Buy$37.5097.37% UpsideNMRANeumora Therapeutics 2.22Hold$7.14211.92% UpsidePVLAPalvella Therapeutics 3.11Buy$47.5022.96% UpsideCurrent Analyst Ratings BreakdownLatest INKT, AMRN, NMRA, and PVLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2025PVLAPalvella TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$56.007/18/2025INKTMiNK TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/16/2025NMRANeumora TherapeuticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$4.00 ➝ $5.007/15/2025INKTMiNK TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Neutral$35.007/11/2025INKTMiNK TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform6/25/2025AMRNAmarinThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSell ➝ Sell$7.00 ➝ $12.005/16/2025PVLAPalvella TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$53.00 ➝ $52.005/13/2025NMRANeumora TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/30/2025PVLAPalvella TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.00(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMRNAmarin$228.61M1.40N/AN/A$23.62 per share0.66INKTMiNK TherapeuticsN/AN/AN/AN/A($4.94) per shareN/ANMRANeumora TherapeuticsN/AN/AN/AN/A$1.78 per shareN/APVLAPalvella Therapeutics$42.81M9.98N/AN/A$5.58 per share6.92Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMRNAmarin-$82.18M-$3.64N/AN/AN/A-41.07%-17.21%-12.16%7/30/2025 (Estimated)INKTMiNK Therapeutics-$9.51M-$2.52N/AN/AN/AN/AN/A-140.72%8/12/2025 (Estimated)NMRANeumora Therapeutics-$243.79M-$1.61N/AN/AN/AN/A-84.79%-77.57%8/5/2025 (Estimated)PVLAPalvella Therapeutics-$17.43M-$12.10N/AN/AN/AN/A-60.29%-43.30%8/13/2025 (Estimated)Latest INKT, AMRN, NMRA, and PVLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025PVLAPalvella Therapeutics-$0.81N/AN/AN/AN/AN/A8/12/2025Q2 2025INKTMiNK Therapeutics-$0.45N/AN/AN/AN/AN/A8/5/2025Q2 2025NMRANeumora Therapeutics-$0.38N/AN/AN/AN/AN/A7/30/2025Q2 2025AMRNAmarin-$0.60N/AN/AN/A$45.45 millionN/A5/15/2025Q1 2025INKTMiNK Therapeutics-$0.61-$0.70-$0.09-$0.70N/AN/A5/15/2025Q1 2025PVLAPalvella Therapeutics-$3.40-$0.74+$2.66-$0.74N/AN/A5/12/2025Q1 2025NMRANeumora Therapeutics-$0.40-$0.42-$0.02-$0.42N/AN/A5/7/2025Q1 2025AMRNAmarin-$0.06-$0.04+$0.02-$0.04$50.75 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMRNAmarinN/AN/AN/AN/AN/AINKTMiNK TherapeuticsN/AN/AN/AN/AN/ANMRANeumora TherapeuticsN/AN/AN/AN/AN/APVLAPalvella TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMRNAmarinN/A3.532.55INKTMiNK TherapeuticsN/A0.300.30NMRANeumora TherapeuticsN/A8.988.98PVLAPalvella TherapeuticsN/A8.848.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMRNAmarin22.25%INKTMiNK Therapeutics2.87%NMRANeumora Therapeutics47.65%PVLAPalvella Therapeutics40.11%Insider OwnershipCompanyInsider OwnershipAMRNAmarin3.30%INKTMiNK Therapeutics22.48%NMRANeumora Therapeutics26.80%PVLAPalvella Therapeutics20.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMRNAmarin36020.71 million20.02 millionOptionableINKTMiNK Therapeutics303.99 million3.09 millionNo DataNMRANeumora Therapeutics108161.75 million118.40 millionOptionablePVLAPalvella TherapeuticsN/A11.06 million8.79 millionN/AINKT, AMRN, NMRA, and PVLA HeadlinesRecent News About These CompaniesTruist Financial Initiates Coverage on Palvella Therapeutics (NASDAQ:PVLA)July 23 at 4:11 AM | americanbankingnews.comPalvella Therapeutics (NASDAQ:PVLA) Now Covered by Truist FinancialJuly 21 at 8:15 AM | marketbeat.comPVLA - Palvella Therapeutics Inc Sustainability - MorningstarJuly 9, 2025 | morningstar.comMPalvella Therapeutics Completes Enrollment for Pivotal Phase 3 Trial of QTORIN RapamycinJuly 9, 2025 | msn.comPalvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Buy" by AnalystsJuly 3, 2025 | marketbeat.comPalvella Therapeutics, Inc. Added to Russell 3000® and Russell 2000® Indexes as of June 30, 2025June 30, 2025 | quiverquant.comQPalvella Therapeutics Added to Russell 3000® and Russell 2000® IndexesJune 30, 2025 | globenewswire.comStrid Group LLC Takes $818,000 Position in Palvella Therapeutics, Inc. (NASDAQ:PVLA)June 29, 2025 | marketbeat.comPVLA - Palvella Therapeutics Inc Key Metrics - MorningstarJune 27, 2025 | morningstar.comMPVLA - Palvella Therapeutics Inc Executives - MorningstarJune 26, 2025 | morningstar.comMPalvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25% | The ...June 24, 2025 | manilatimes.netMPalvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by ... - MorningstarJune 24, 2025 | morningstar.comMPalvella Therapeutics Completes Enrollment for Phase 3 Trial of QTORIN™ Rapamycin in Microcystic Lymphatic Malformations, Anticipates Top-Line Data in 2026 - NasdaqJune 24, 2025 | nasdaq.comPalvella Therapeutics Announces Completion of Phase 3 SELVA Trial for QTORIN RapamycinJune 24, 2025 | msn.comPalvella Therapeutics Completes Enrollment for Phase 3 Trial of QTORIN™ Rapamycin in Microcystic Lymphatic Malformations, Anticipates Top-Line Data in 2026June 23, 2025 | quiverquant.comQPalvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%June 23, 2025 | globenewswire.comPalvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR InhibitorsJune 18, 2025 | globenewswire.comPalvella Therapeutics Secures FDA Grant Funding for Phase 3 Trial of QTORIN RapamycinJune 13, 2025 | msn.comPalvella Therapeutics Secures FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ for Microcystic Lymphatic MalformationsJune 9, 2025 | quiverquant.comQPalvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic MalformationsJune 9, 2025 | globenewswire.comPalvella Therapeutics Advances in Rare Skin Disease TherapiesMay 30, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINKT, AMRN, NMRA, and PVLA Company DescriptionsAmarin NASDAQ:AMRN$15.50 -0.09 (-0.58%) Closing price 04:00 PM EasternExtended Trading$15.33 -0.17 (-1.10%) As of 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.MiNK Therapeutics NASDAQ:INKT$19.00 -1.06 (-5.28%) Closing price 04:00 PM EasternExtended Trading$19.08 +0.07 (+0.39%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.Neumora Therapeutics NASDAQ:NMRA$2.29 +0.44 (+23.78%) Closing price 04:00 PM EasternExtended Trading$2.27 -0.02 (-0.92%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.Palvella Therapeutics NASDAQ:PVLA$38.63 +0.20 (+0.52%) As of 04:00 PM EasternPalvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Alphabet’s Breakout Quarter Signals a New Leadership Phase Tesla Just Hit a Fork in the Road—Could the Bulls Lose Control? GE Vernova's Q2 Electrifies Stock, What's Next For This Top Name? Is Former Dividend Aristocrat AT&T a Buy After Q2 Earnings? What's Behind Opendoor Technologies' Rally? Is Meme Mania Back? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
